S&P 500   3,659.04 (-0.09%)
DOW   29,789.71 (-0.11%)
QQQ   303.15 (-0.10%)
AAPL   123.03 (+0.25%)
MSFT   214.08 (-0.99%)
FB   288.02 (+0.51%)
GOOGL   1,824.13 (+1.60%)
AMZN   3,209.37 (-0.33%)
TSLA   561.14 (-4.04%)
NVDA   542.20 (+1.23%)
BABA   261.72 (-0.87%)
CGC   28.43 (+6.68%)
GE   10.36 (+2.07%)
MU   68.43 (+2.01%)
AMD   93.86 (+1.33%)
T   28.94 (+0.24%)
NIO   46.52 (+2.56%)
F   9.18 (-0.65%)
ACB   11.25 (+15.38%)
NFLX   502.75 (-0.36%)
BA   218.96 (+2.79%)
GILD   61.17 (+0.08%)
DIS   152.42 (+1.99%)
S&P 500   3,659.04 (-0.09%)
DOW   29,789.71 (-0.11%)
QQQ   303.15 (-0.10%)
AAPL   123.03 (+0.25%)
MSFT   214.08 (-0.99%)
FB   288.02 (+0.51%)
GOOGL   1,824.13 (+1.60%)
AMZN   3,209.37 (-0.33%)
TSLA   561.14 (-4.04%)
NVDA   542.20 (+1.23%)
BABA   261.72 (-0.87%)
CGC   28.43 (+6.68%)
GE   10.36 (+2.07%)
MU   68.43 (+2.01%)
AMD   93.86 (+1.33%)
T   28.94 (+0.24%)
NIO   46.52 (+2.56%)
F   9.18 (-0.65%)
ACB   11.25 (+15.38%)
NFLX   502.75 (-0.36%)
BA   218.96 (+2.79%)
GILD   61.17 (+0.08%)
DIS   152.42 (+1.99%)
S&P 500   3,659.04 (-0.09%)
DOW   29,789.71 (-0.11%)
QQQ   303.15 (-0.10%)
AAPL   123.03 (+0.25%)
MSFT   214.08 (-0.99%)
FB   288.02 (+0.51%)
GOOGL   1,824.13 (+1.60%)
AMZN   3,209.37 (-0.33%)
TSLA   561.14 (-4.04%)
NVDA   542.20 (+1.23%)
BABA   261.72 (-0.87%)
CGC   28.43 (+6.68%)
GE   10.36 (+2.07%)
MU   68.43 (+2.01%)
AMD   93.86 (+1.33%)
T   28.94 (+0.24%)
NIO   46.52 (+2.56%)
F   9.18 (-0.65%)
ACB   11.25 (+15.38%)
NFLX   502.75 (-0.36%)
BA   218.96 (+2.79%)
GILD   61.17 (+0.08%)
DIS   152.42 (+1.99%)
S&P 500   3,659.04 (-0.09%)
DOW   29,789.71 (-0.11%)
QQQ   303.15 (-0.10%)
AAPL   123.03 (+0.25%)
MSFT   214.08 (-0.99%)
FB   288.02 (+0.51%)
GOOGL   1,824.13 (+1.60%)
AMZN   3,209.37 (-0.33%)
TSLA   561.14 (-4.04%)
NVDA   542.20 (+1.23%)
BABA   261.72 (-0.87%)
CGC   28.43 (+6.68%)
GE   10.36 (+2.07%)
MU   68.43 (+2.01%)
AMD   93.86 (+1.33%)
T   28.94 (+0.24%)
NIO   46.52 (+2.56%)
F   9.18 (-0.65%)
ACB   11.25 (+15.38%)
NFLX   502.75 (-0.36%)
BA   218.96 (+2.79%)
GILD   61.17 (+0.08%)
DIS   152.42 (+1.99%)
Log in
ARCA:ANVS

Annovis Bio Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume24,753 shs
Market Capitalization$35.63 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. Its lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. The company is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. Annovis Bio, Inc. was founded in 2008 and is based in Berwyn, Pennsylvania.

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.17 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone610 727 3913
Employees2

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.32 per share

Profitability

Net Income$-990,000.00

Miscellaneous

Market Cap$35.63 million
Next Earnings DateN/A
OptionableNot Optionable
30 days | 90 days | 365 days | Advanced Chart

Receive ANVS News and Ratings via Email

Sign-up to receive the latest news and ratings for ANVS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Annovis Bio (ARCA:ANVS) Frequently Asked Questions

What stocks does MarketBeat like better than Annovis Bio?

Wall Street analysts have given Annovis Bio a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Annovis Bio wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Annovis Bio's key competitors?

Who are Annovis Bio's key executives?

Annovis Bio's management team includes the following people:
  • Dr. Maria L. MacCecchini, Founder, CEO, Pres & Director (Age 69, Pay $120k)
  • Mr. Jeffrey B. McGroarty CPA, Chief Financial Officer (Age 51)
  • Dr. Jeffrey L. Cummings, Chief Medical Officer & Member of Scientific Advisory Board (Age 71)
  • Dr. William C. Mobley, Chief Scientific Advisor & Member of Scientific Advisory Board

What is Annovis Bio's stock symbol?

Annovis Bio trades on the ARCA under the ticker symbol "ANVS."

How do I buy shares of Annovis Bio?

Shares of ANVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

How big of a company is Annovis Bio?

Annovis Bio has a market capitalization of $0.00. Annovis Bio employs 2 workers across the globe.

What is Annovis Bio's official website?

The official website for Annovis Bio is www.annovisbio.com.

How can I contact Annovis Bio?

Annovis Bio's mailing address is 1055 Westlakes Drive Suite 300, Berwyn PA, 19312. The company can be reached via phone at 610 727 3913 or via email at [email protected]

This page was last updated on 12/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.